Close Menu

NEW YORK – Rain Therapeutics said on Wednesday that it has licensed worldwide rights to Daiichi Sankyo's investigational MDM2 inhibitor milademetan, which it will evaluate in solid and hematologic cancers with MDM2 amplification or overexpression.

The Newark, California-based biotechnology firm's global license extends to all indications under evaluation within the milademetan program, which the firm will rename RAIN-32. The financial terms of the deal were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.